03 October 2017 : Original article
Induction of Artificial Pancreas in Liver Transplant Recipients: Preliminary Experience with an Insightful Message
Hironori Hayashi1ABCDEFG*, Hiroyuki Takamura1ACDFG, Ryosuke Gabata1B, Isamu Makino1BC, Yoshinao Ohbatake1BC, Shinichi Nakanuma1BC, Tomoharu Miyashita1CD, Hidehiro Tajima1CDF, Kazuhiro Hanazaki2ADEF, Tetsuo Ohta1ADFGDOI: 10.12659/AOT.906083
Ann Transplant 2017; 22:590-597
Abstract
BACKGROUND: We investigated the impact of using an artificial pancreas for glycemic control in liver transplant recipients.
MATERIAL AND METHODS: Between January 2014 and December 2016, glycemic control using an artificial pancreas was performed 13 times. The target blood glucose level was set at 80–110 mg/dL. We retrospectively analyzed the clinical course, including achievement rate of the target blood glucose range.
RESULTS: For perioperative glycemic control, an artificial pancreas was used 9 times. The total insulin dose and achievement rate of the target blood glucose level were 113.9±51.4 U and 23.7±15.6%, per 24 h, respectively. Additionally, recipients with infectious complications (n=2) and rejection treated with methylprednisolone pulse therapy (n=2) received glycemic control using an artificial pancreas. The total insulin dose and achievement rate of the target blood glucose level were 156.5±57.5 U and 20.2±20.0% per 24 h, respectively. No hypoglycemia occurred during this period.
CONCLUSIONS: Application of an artificial pancreas for liver transplant recipients was safe, with no hypoglycemia. The results suggest that occurrence of marked insulin resistance in liver transplant recipients should be prevented for better outcomes.
Keywords: Diabetes Mellitus, Insulin Resistance, Liver Transplantation, Postoperative Complications
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588